Literature DB >> 10545480

Protective immune correlates can segregate by vaccine type in a murine herpes model system.

J I Sin1, V Ayyavoo, J Boyer, J Kim, R B Ciccarelli, D B Weiner.   

Abstract

A central tenet of vaccine development is to identify immune correlates of protection. Both plasmid-encoded gD as well as recombinant protein gD can protect mice from lethal herpes simplex virus (HSV) challenge. It is known that different vaccine modalities should induce different immune phenotypes. Yet, paradoxically, it is also thought that the basis for protection should rely on exploitation of vulnerabilities of the pathogen and therefore that the overlapping properties of these different vaccines would reveal insight into common immune mechanisms responsible for protection. We sought to investigate this question by comparing two different vaccine modalities in the HSV-2 mouse model. We observed that gD protein was a strong inducer of T(h)2-type immune responses, and overall antibody titers of IgG, IgE and IgA were significantly higher than those induced by plasmid gD vaccines. In contrast, the plasmid gD vaccine induced a strong T(h)1 bias. Following high-dose challenge the gD protein was most effective at providing protection. However, at lower lethal dose challenge, while both vaccines were protective with regards to survival, only the plasmid-vaccinated animals were protected from HSV-2 infection-induced morbidity. These studies suggest that these different vaccine modalities induce protection through unique non-overlapping mechanisms, supporting that vaccine correlates are associated with the types of immunogen rather than solely the pathogen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545480     DOI: 10.1093/intimm/11.11.1763

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo.

Authors:  J I Sin; J Kim; C Pachuk; D B Weiner; C Patchuk
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

3.  Immunogenicity of a bovine herpesvirus 1 glycoprotein D DNA vaccine complexed with bovine neutrophil beta-defensin 3.

Authors:  Sarah Mackenzie-Dyck; Laura Latimer; Ethel Atanley; Jennifer Kovacs-Nolan; Sam Attah-Poku; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

Review 4.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo.

Authors:  J Sin; J J Kim; C Pachuk; C Satishchandran; D B Weiner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production.

Authors:  Si-Hyeong Lee; Baek-Sang Han; Jongseon Choe; Jeong-Im Sin
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

Review 8.  Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.

Authors:  Aziz Alami Chentoufi; Lbachir Benmohamed
Journal:  Clin Dev Immunol       Date:  2012-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.